Derma Sciences Inc. (DSCI) Upgraded to Buy at Zacks Investment Research
Zacks Investment Research upgraded shares of Derma Sciences Inc. (NASDAQ:DSCI) from a hold rating to a buy rating in a research report report published on Tuesday. Zacks Investment Research currently has $5.25 price target on the stock.
According to Zacks, “Derma Sciences, Inc. is engaged in the development, marketing and sales of proprietary and non-proprietary topical, nutrient-based wound care products for the management of certain chronic, non-healing skin ulcerations such as pressure and venous ulcers, surgical incisions and burns. (PRESS RELEASE) “
Separately, TheStreet upgraded Derma Sciences from a sell rating to a hold rating in a report on Tuesday, August 9th. Three investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Derma Sciences currently has a consensus rating of Buy and a consensus target price of $7.25.
Shares of Derma Sciences (NASDAQ:DSCI) opened at 4.65 on Tuesday. Derma Sciences has a 1-year low of $2.85 and a 1-year high of $5.99. The firm has a 50-day moving average price of $4.68 and a 200-day moving average price of $4.24. The company’s market capitalization is $131.62 million.
Derma Sciences (NASDAQ:DSCI) last posted its earnings results on Tuesday, August 9th. The company reported $0.08 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.08) by $0.16. Derma Sciences had a negative return on equity of 11.74% and a negative net margin of 21.19%. The firm earned $22.20 million during the quarter, compared to analyst estimates of $22.40 million. Equities analysts anticipate that Derma Sciences will post ($0.04) earnings per share for the current year.
Several hedge funds have recently added to or reduced their stakes in the stock. BlackRock Institutional Trust Company N.A. boosted its stake in Derma Sciences by 2.4% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 153,052 shares of the company’s stock worth $603,000 after buying an additional 3,613 shares in the last quarter. Vanguard Group Inc. boosted its stake in Derma Sciences by 1.1% in the second quarter. Vanguard Group Inc. now owns 802,878 shares of the company’s stock worth $3,163,000 after buying an additional 8,376 shares in the last quarter. Dimensional Fund Advisors LP boosted its stake in Derma Sciences by 15.6% in the second quarter. Dimensional Fund Advisors LP now owns 52,535 shares of the company’s stock worth $207,000 after buying an additional 7,086 shares in the last quarter. Emerald Acquisition Ltd. purchased a new stake in Derma Sciences during the second quarter worth about $202,000. Finally, Jacobs Levy Equity Management Inc. boosted its stake in Derma Sciences by 170.5% in the first quarter. Jacobs Levy Equity Management Inc. now owns 117,271 shares of the company’s stock worth $364,000 after buying an additional 73,911 shares in the last quarter. Institutional investors and hedge funds own 62.44% of the company’s stock.
Derma Sciences Company Profile
Derma Sciences, Inc (Derma Sciences) is a medical device company. The Company operates through two segments: advanced wound care and traditional wound care products. Advanced wound care products principally consist of both novel and otherwise differentiated dressings, devices and skin substitutes designed to promote wound healing and/or prevent infection.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Derma Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Derma Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.